Core Insights - Clearmind Medicine Inc. has announced a patent publication for a combination therapy involving MEAI and N-Acylethanolamines, targeting binge behaviors such as alcohol consumption and shopping [1][2] - The patent is a result of collaboration with SciSparc Ltd., focusing on integrating psychedelic compounds with N-Acylethanolamines [2] - Clearmind's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as opportunities arise [4] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing psychedelic-derived therapeutics aimed at addressing significant health issues, including alcohol use disorder [3] - The company aims to commercialize its psychedelic-based compounds as regulated medicines, foods, or supplements [3] Collaboration Details - The partnership with SciSparc Ltd. is centered on researching innovative therapies that combine psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide [2] - SciSparc Ltd. focuses on cannabinoid pharmaceuticals and is involved in various drug development programs targeting central nervous system disorders [5]
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico